Jeroncellvein (CEO Deok-gyu Kim) , a specialized pharmaceutical manufacturer, announced on the 30th that it had completed its exhibition and lecture schedule at the 'Association of Korean Society for Aesthetic Laser Medicine Japan Conference (ASLS TOKYO 2025)' held in Tokyo, Japan from the 26th.
At this academic conference, GeronCellvane gave a lecture on the topic of 'Clinical Cases of PDRN Skin Booster and PN Filler' and introduced its main products on site. The products introduced through the exhibition booth were PDRN-based 'Cellvane Skin Booster', export PN healer 'Kledence', and prescription drug 'Cellvane Inj.', and it is explained that they received a lot of interest from medical professionals in both Korea and Japan.
GeronCelvein applies its own Prism Technology (Prism-T) to its products, which is a technology that implements high absorption rate and safety through a uniform and small molecular structure. In particular, 'Celvein Injection' is used in the dermatology and pain treatment fields due to its tissue regeneration effect.
'ASLS TOKYO 2025' is the first academic conference hosted by the Korean Society of Aesthetic Plastic Surgery Laser Medicine in Japan, and was held with the goal of exchanging knowledge between Korean and Japanese medical professionals and spreading aesthetic medical technology. Approximately 500 medical professionals attended the event, and Geroncellbein stated that it was an opportunity to promote its technological prowess and product competitiveness through lectures and exhibitions.
Kim Deok-gyu, CEO of Jeroncellbein, said, “Through participation in this academic conference, we have created an opportunity to increase brand awareness and reliability in the Japanese market,” and “We will continue to develop high value-added products based on regenerative medicine technology and expand our presence in the global market in the future.”
- See more related articles
You must be logged in to post a comment.